Therapeutic agent of uremia containing alarin as the main ingredient

Abstract

The present invention relates to a novel use of alarin derived from a splice variant of galanin-like peptide (GALP) RNA and thus having an amino acid sequence similar to that of galanin, with a therapeutic agent of uremia, and the therapeutic agents of uremia according to the present invention include alarin as the main ingredient.

Description

TECHNICAL FIELD[0001]The present invention relates to a therapeutic agent of uremia containing alarin as the main ingredient, and more particularly, to the use of alarin as a therapeutic agent of uremia with a new use of alarin derived from a splice variant of galanin-like peptide (GALP) RNA and having an amino acid sequence similar to galanin.BACKGROUND ART[0002]Despite of the development of medical technology, there are no effective method of treatments for many diseases yet, and such intractable diseases may include uremia. Uremia refers to a syndrome that shows various clinical symptoms resulting from abnormal expression for functions of various organs and tissues caused by harmful components of urine accumulated in blood, which are occurred when the urine cannot be discharged outside the body due to the breakdown of kidney function whatever the underlying disease. The clinical symptoms of uremia include, for example, digestive system abnormalities such as anorexia, nausea, vomi...

AI Technical Summary

Problems solved by technology

Despite of the development of medical technology, there are no effective method of treatments for many diseases yet, and such intractable diseases may include uremia.

However, it is still unclear which of these urea substances are intrinsically involved in the development of uremic symptoms, and it is unknown whether uresis occurs only by a single substance or by a complex action of these plural substances.

These facts show clearly the difficulty of treating uremia with medicine.

Whatever its development of occurrence, a person with uremia can face a fatal situation that leads to death, unless the urinary substance is released out of the body or the concentration of the urea in the blood is reduced by appropriate means.

However, activated charcoal agents are used as internal medicines, and the mechanism of action of activated charcoal agent is by adsorption and in vitro excretion of various toxic substances generated in the digestive organs.

In addition to that the activated charcoal agent is limited for therapeutic effect, there are several problems such as difficulty in taking them and a tendency to cause constipation, and thus it are not very satisfactory treatments.

However, complications caused by dialysis are becoming a new problem.

In addition, there is a problem in the medical economy such as the low quality of the patient's social life and the occurrence of high treatment costs that should visit frequently in the dialysis facility.

However, the enteropulling action is an action of storing a moisture in the digestive tract, and therefore, it inevitably involves diarrhea and the reporter also mentions this point.

Moreover, no matter how much blood serum Cre or BUN values are lowered, long-term treatment of this remedy which involves risk of physical depletion and dehydration due to diarrhea is very burdensome for patients with chronic renal failure and then is hard to be recognized as practically acceptable treatment.

However, the invention disclosed in the above Patent Document 1 still has a problem in that it is difficult to provide a satisfactory treatment effect for uremia, and thus there is still a need for a therapeutic agent having excellent treatment effect of uremia with long-term use without causing other side effects.

Images